Strong Revenue Growth:
Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.
Investor Backing & Capital Strength:
Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.
Market Expansion:
Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.
.png)
.png)
